...
首页> 外文期刊>BMC Cancer >Personalised informed choice on evidence and controversy on mammography screening: study protocol for a randomized controlled trial
【24h】

Personalised informed choice on evidence and controversy on mammography screening: study protocol for a randomized controlled trial

机译:证据方面的个性化知情选择和乳房X线筛查的争议:一项随机对照试验的研究方案

获取原文
           

摘要

Background In Italy women aged 50–69 are invited for a population-based breast cancer (BC) screening. Physicians, policy makers and patients associations agree on the need to inform women about the benefits and harms in order to permit an informed decision. Decision aids (DA) are an effective way to support people in their decisions about health. This trial aims to assess women’s informed choices, according to their health literacy and values, on participating or not in BC screening for the first time. Benefits, harms and controversies are presented. Methods/design The impact of the DA will be evaluated in a randomized controlled trial with a two-week follow-up. Women will be randomized via web to DA or a standard brochure. We will invite 8160 women, to obtain a final sample of 816 women. The primary outcome will be informed choice, measured on the basis of knowledge, attitudes and intentions on BC screening. Secondary outcomes are participation rate, satisfaction on information and decisional conflict. Discussion The web DA will be open-source and implemented on BC screenings and its efficacy for increasing informed choice will be tested. This model could be applied to other healthcare settings, cancer screenings, and public health programs. Trial registration The protocol for this trial was registered with the Clinicaltrials.gov registry on March 16, 2017: NCT03097653 .
机译:背景技术在意大利,邀请50-69岁的女性进行基于人群的乳腺癌(BC)筛查。内科医生,政策制定者和患者协会同意必须告知妇女其利弊,以便作出明智的决定。决策辅助工具(DA)是支持人们做出健康决定的有效方法。这项试验旨在根据女性的健康素养和价值观,评估他们是否首次参与BC筛查的知情选择。提出了利益,危害和争议。方法/设计DA的影响将在为期两周的随机对照试验中进行评估。妇女将通过网络随机分配到DA或标准手册中。我们将邀请8160名女性,最终获得816名女性的样本。主要结果将是根据对BC筛查的知识,态度和意图进行衡量的知情选择。次要结果是参与率,信息满意度和决策冲突。讨论Web DA将是开源的,并将在BC筛选中实现,并将测试其在增加明智选择方面的功效。该模型可以应用于其他医疗机构,癌症筛查和公共卫生计划。试验注册该试验的方案已于2017年3月16日在Clinicaltrials.gov注册中心进行了注册:NCT03097653。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号